Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs have been gaining popularity in Albania in recent years, with a significant increase in demand observed across the country.
Customer preferences: Bronchodilator drugs are primarily used to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. With the rise in air pollution and smoking habits in Albania, the number of people suffering from respiratory diseases has increased, leading to a surge in demand for bronchodilator drugs. Additionally, the aging population in the country has also contributed to the growth of the market as older adults are more prone to respiratory illnesses.
Trends in the market: The bronchodilator drugs market in Albania has been witnessing a shift towards long-acting beta-agonists (LABA) and long-acting muscarinic antagonists (LAMA) due to their prolonged effect and ease of use. Combination drugs that contain both LABA and inhaled corticosteroids (ICS) have also been gaining popularity in the country. Moreover, the market has been witnessing the introduction of new products with improved efficacy and fewer side effects.
Local special circumstances: One of the major challenges in the Albanian market is the lack of awareness about respiratory diseases and their treatment options. This has resulted in many people not seeking medical help until their condition worsens, leading to higher healthcare costs and increased morbidity. Additionally, the cost of bronchodilator drugs remains a concern for many patients as they are not covered under the national health insurance scheme.
Underlying macroeconomic factors: The Albanian pharmaceutical market has been growing steadily, driven by an increase in healthcare spending and the implementation of healthcare reforms. The government has been investing in the healthcare sector to improve access to healthcare services and reduce the burden of disease. Furthermore, the country's accession to the European Union has led to the harmonization of pharmaceutical regulations, making it easier for pharmaceutical companies to operate in the country. These factors have contributed to the growth of the bronchodilator drugs market in Albania.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
